Comparative characteristics of the molecular biological portrait of the head and neck squamous cell carcinoma tumorand peritumoral tissue
- Authors: Jumaniyazova E.D.1, Arutyunyan I.V.1,2, Soboleva A.G.1,2, Vishnyakova P.A.1,3, Gulieva M.A.1, Lokhonina A.V.1, Makarov A.V.1,4, Gordon K.B.1,5
-
Affiliations:
- RUDN University
- Avtsyn Research Institute of Human Morphology, Petrovsky National Research Centre of Surgery
- V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology and Perinatology
- Pirogov Russian National Research Medical University
- A. Tsyb Medical Radiological Research Center, National Medical Research Center of Radiology
- Issue: Vol 30, No 3 (2026): CELL BIOLOGY
- Pages: 314-327
- Section: CELL BIOLOGY
- URL: https://journals.rudn.ru/medicine/article/view/52066
- DOI: https://doi.org/10.22363/2313-0245-2025-30-3-314-327
- EDN: https://elibrary.ru/KBUNAB
- ID: 52066
Cite item
Full Text
Abstract
Relevance. Head and neck squamous cell cancer (HNSCC) accounts for about 890,000 new cases of malignant neoplasms (approximately 4.5% of all diagnosed cancer cases worldwide) and 450,000 deaths per year. Even with radical antitumor treatment, more than 40-50% of patients develop relapse, 20-30% of them develop distant metastases, and the five-year survival rate in advanced cases is 25%. Patients with recurrent HNSCC have an unfavorable clinical prognosis with a median overall survival of about 12 months. A high recurrence rate indicates the possible existence of a “sourceˮ of tumor cells, which may be located near the primary tumor, namely in the peritumoral tissue, which necessitates its study. The aim of the study was to compare the structure and expression of genes in the tumor and peritumoral tissues of HNSCC. Materials and methods. Biopsy material of tumor and peritumoral (located at a distance of 2 cm from the tumor border) tissues was obtained from 35 patients with HNSCC. Biopsies were examined by histological method, then the levels of mRNA expression of EGFR, PIK3CA, PTEN, YAP, SLC26A6, ARIH2, UBE2Z, PITX1 genes were determined by real-time polymerase chain reaction in samples of tumor tissue and peritumoral region. The RNA Solo kit was used for RNA isolation, and the MMLV RT Kit (Evrogen, Russia) was used for reverse transcription. The amplification reaction with real-time detection was performed on a Real-Time DTprime amplifier (DNA Technology, Russia). Results and discussion. All tumor samples, regardless of anatomical localization, exhibited characteristic morphological features of squamous cell carcinoma. The peritumoral specimens represented visually unchanged tissue with preserved epithelial architecture. The expression of EGFR and PIK3CA genes was higher in tumor tissue samples, while PITX1 expression was higher in peritumoral tissue samples. Conclusion. Increased expression of EGFR and PIK3CA genes in tumor tissue confirms the activation of signaling pathways associated with tumor cell proliferation, survival, and disease progression. In contrast, the higher expression of the putative tumor suppressor gene PITX1 in peritumoral tissue suggests the preservation of regulatory mechanisms limiting malignant transformation outside the tumor focus.
Full Text
Introduction
The most common morphological form of tumors of the head and neck is squamous cell carcinoma. According to data published by GLOBOCAN (2020), head and neck squamous cell carcinoma (HNSCC) ranks sixth in prevalence among other types of malignant neoplasms in the world. According to current data, HNSCC accounts for an estimated 890 000 incident cases of malignant neoplasms per annum, corresponding to approximately 4.5% of the global incidence of diagnosed cancers, and approximately 450 000 cancer-related deaths annually [1]. This type of cancer is more common in adults over 50 years of age, with a male-dominated gender ratio (the ratio of men to women is approximately 2:1) [2]. To date, the increase in the incidence of acute respiratory viral infections among young able-bodied people has become socially significant. The main generally recognized etiological factors are tobacco smoking, alcohol consumption, infection with human papillomavirus (HPV) or Epstein-Barr virus (EBV), as well as betel chewing, common among the peoples of Southeast Asia. Clinically, HNSCC is characterized by late diagnosis, aggressive course, locally widespread growth pattern, and frequent relapses [3]. The lack of screening leads to late diagnosis, complex anatomical localization complicates the radical surgical stage of treatment, and the proximity of critical structures leads to complications during RT. In the early stages of HNSCC (stages I and II), surgical treatment and RT are highly effective, with one- and two-year survival rates of 88.7 and 79.8%, respectively [4]. However, more than half of the patients (approximately 2/3 of the patients) already have a locally advanced form of the disease (stages III and IV) at the time of diagnosis, which is a prognostically unfavorable factor. Even with radical antitumor treatment, more than 40–50% of patients develop relapse, 20–30% of them develop distant metastases [5, 6], and the overall five-year survival rate is 25%. Patients with recurrent HNSCC have an unfavorable clinical prognosis with a median overall survival of about 12 months [7]. It was shown that in the most unfavorable cohort of patients (with a low–grade tumor negative for HPV type 16), the recurrence rate in the first six months after treatment is 50.6%, within 1 year — 72.5%, within 2 years — 88.6%. Such statistical data indicate the possible existence of a source of preserved or, conversely, induced by the therapeutic effect of tumor cells, which may be located near the localization of the primary tumor, namely, in the peritumoral tissue, which necessitates its study.
The aim of our study was to compare the structure and expression of genes in the tumor and peritumoral tissues of squamous cell carcinoma of the head and neck.
Based on a literature review, genes were selected that play a key role in tumor progression, including long-known regulators of tumor progression, as well as genes whose role in tumor growth has become known relatively recently.
Materials and methods
Characteristics of the biomaterial
The biopsy material of the tumor and peritumoral tissue (located at a distance of 2 cm from the tumor border) of the patients was obtained from the A. Tsyb Medical Radiological Research Center (MRSC). During the study, biomaterials from 35 patients obtained during the surgical stage of treatment were analyzed, information about patients is presented in the Table 1.
Biomaterial was obtained from patients meeting the following criteria:
- Men and women over the age of 18.
- Morphologically or radiologically verified diagnosis of squamous cell carcinoma in the head and neck (C00-C14, C30-C33).
- General condition on the Karnovsky scale of at least 70 points.
- Informed consent to participate in the study.
Table 1
General characteristics of patients
Parameters | Patients n, % |
Total quantity | 35 (100%) |
Gender | |
Men Women | 22 (62.8%) |
Age (years) | |
Median Range | 57.3 19—83 |
Grade of malignancy | |
G1 G2 G3 | 25 (71.4.4%) 8 (22.8.8%) 2 (5.7.7%) |
Keratinization | |
Keratinizing Non-keratinizing | 17 (48.57%) 18 (51.4%) |
T stage | |
1 2 3 4 | 3 (8.57%) 15 (42.8%) 10 (28.5%) 7 (20%) |
N stage | |
0 1 2 | 9 (25.7%) 18 (51.4%) 8 (22.8%) |
M stage | |
0 1 | 22 (62.8%) 13 (37.2%) |
Localization | |
Oral cavity Tongue Larynx Maxillary sinus | 15 (42.8%) 8 (22.8%) 10 (28.5%) 2 (5.7%) |
Primary processing of the received material
The material was thoroughly washed from possible contaminating agents in a phosphate-salt buffer containing 0.02% EDTA (Versin solution), then in a phosphate-salt buffer containing 1× antibiotic-antimycotic, then in a phosphate-salt buffer or Hanks solution without additives. In each solution, the tissue was washed 3 times. Then the material was divided into 2 unequal parts: the fragment was preserved in RNAlater solution for subsequent PCR-RT and stored at –80˚C until the study, the rest of the tissue was used for morphological examination.
Morphological examination
To verify the diagnosis of squamous cell carcinoma, a histological examination of the obtained tissue samples (tumor and peritumoral) was performed. Unfixed tissue samples were transferred to a foil mold filled with Tissue-Tek O.C.T. Compound (Sakura Finetek), frozen at –80 °C until the mounting medium completely solidified, then stored at –20 °C until use. Cryosections with a thickness of 5 microns were made using a Leica CM1200 cryotome using Super Frost Gold (Menzel) glasses and dried at room temperature for 1 hour. For routine histological examination, cryosections were stained with hematoxylin and eosin, dehydrated in standard wiring, and enclosed in a mounting medium (Biovitrum). The survey was carried out using a Leica DM 4000 B direct microscope.
PCR-RT
The levels of mRNA expression of EGFR, PIK3CA, PTEN, YAP, SLC26A6, ARIH2, UBE2Z, and PITX1 genes were determined using real-time polymerase chain reaction in samples of tumor tissue and the peritumoral region (Table 2). The RNA Solo kit was used for RNA isolation, and the MMLV RT Kit (Evrogen, Russia) was used for reverse transcription. The amplification reaction with real-time detection was performed on a Real-Time DTprime amplifier (DNA Technology, Russia). The relative mRNA concentration of these genes was calculated by direct data comparison using the formula: [A]0/[B]0 = E DC(T), where [A]0 is the initial concentration of the gene's mRNA in the PCR mixture, [B]0 is the initial concentration of GAPDH mRNA in the PCR mixture, E is the reaction efficiency (assumed to be 1.98), DC(T) is the difference between the threshold cycles of GAPDH and the desired gene.
Table 2
Sequences of used primers
Gene | Sequence | |
GAPDH | Forward | GCACCGTCAAGGCTGAGAAC |
Reverse | TGGTGAAGACGCCAGTGGA | |
EGFR | Forward | CCCCCTGACTCCGTCCAGTA |
Reverse | CCCAACTGCGTGAGCTTGTT | |
PIK3CA | Forward | TTCCGGGGGATTGTAGGCTC |
Reverse | TTCCGGGGGATTGTAGGCTC | |
YAP | Forward | CAGCAACTCCAACCAGCAGC |
Reverse | CAGCAACTCCAACCAGCAGC | |
SLС26A6 | Forward | AGACAGCCAGAGATGCTGCC |
Reverse | GTAGGTGACCACGAAGCCGA | |
UBE2Z | Forward | CGGCACGAGACCATCAGAGT |
Reverse | TGGTAGTCAAAGTGGCCCCG | |
PTEN | Forward | CCCAGTCAGAGGCGCTATGT |
Reverse | CCCAGTCAGAGGCGCTATGT | |
TIMP1 | Forward | CCTTCCAGGTGTTTCCCTGTT |
Reverse | CCTTCCAGGTGTTTCCCTGTT | |
TIMP2 | Forward | GACCCACAAGGAGATTGGGG |
Reverse | GACCCACAAGGAGATTGGGG | |
PITX1 | Forward | AACCGCTACCCCGACATGAG |
Reverse | CTGCACTAGGCCGCTGAACT | |
Statistical methods
The statistical analysis of the obtained data was carried out in the Statistica 8.0 program, using the Shapiro – Wilk test to assess the normality of the distribution, the Mann – Whitney criteria and the t-test for pairwise comparison. The differences were considered statistically significant at a significance level of p<0.05.
Results and discussion
In all the presented samples of tumor tissue, extensive invasion of tumor cells into their own plate of the mucous membrane was noted, and the integrity of the basement membrane was disrupted (Figure 1, 2). Histological preparations stained with hematoxylin and eosin revealed a pattern characteristic of squamous cell carcinoma: abundant invasive growth of tumor cells into the underlying tissues in the form of rounded clusters, strands or individual cells. Normal architectonics were preserved in the peritumoral tissue samples: the multilayer epithelium is separated from its own plate of the mucous membrane by a preserved basement membrane (Figure 1, 2).
Figure 1. Squamous cell carcinoma of the larynx: tumor (а) and peritumoral (b) tissues. Hematoxylin and eosin staining. Light-field microscopy. The length of the scale segment is 100 microns and 50 microns
Figure 2. Squamous cell carcinoma of the tongue: tumor (a) and peritumoral (b) tissues. Hematoxylin and eosin staining. Light-field microscopy. The length of the scale segment is 100 microns and 50 microns
The levels of mRNA expression of the PTEN, TIMP1, TIMP2, YAP, PIK3CA, EGFR, ARIH2, SLC26A6, UBE2Z, and PITX1 genes were evaluated using real-time polymerase chain reaction in tumor tissue and peritumoral tissue samples.
PTEN is a tumor suppressor gene that regulates the cell cycle and apoptosis by modulating the PI3K-PKB/Akt signaling pathway. Approximately 30% of cases of HNSCC have decreased PTEN expression. Moreover, the lack of PTEN expression often leads to the development of aggressive tumors and is associated with low disease-free and overall survival of patients [8, 9].
YAP is a transcriptional coactivator of genes involved in growth and tumor formation. Increased YAP expression is associated with an unfavorable prognosis of HNSCC and resistance to chemo and radiotherapy [10] (Figure 3).
Figure 3. The level of relative expression of the PTEN, YAP genes in tumor and peritumoral tissues
Tissue metalloproteinase inhibitors (TIMPs) block the activity of matrix metalloproteinases, which leads to suppression of tumor progression [11], but their role in HNSCC is controversial. There was no significant difference in the expression of these genes in the samples of tumor and peritumoral tissues studied by us (Figure 4).
Figure 4. The level of relative expression of the TIMP1 and TIMP2 genes in tumor and peritumoral tissues
PIK3CA is one of the most frequently mutating oncogenes in PRGS: mutations were detected in 13.7% of cases (TCGA, Firehose Legacy). PIK3CA encodes p110a, a Class 1A PI3K catalytic subunit. With abnormal activation, PI3K stimulates several downstream signaling cascades, which leads to uncontrolled proliferation, survival, and migration of tumor cells [12].
We found that the expression level of the epidermal growth factor receptor (EGFR) is significantly higher in tumor tissue than in peritumoral tissue (Figure 5). EGFR is overexpressed in more than 90% of cases of HNSCC, and its increased expression correlates with an unfavorable outcome in patients [13]. Binding of ligands to EGFR leads to a conformational change in the receptor, followed by autoactivation of tyrosine kinase from the intracellular domain of the receptor. This process activates the intracellular signaling pathway, which leads to inhibition of apoptosis, activation of cell proliferation and angiogenesis, as well as to an increase in the potential for metastatic spread [14].
Figure 5. The level of relative expression of PIK3CA and EGFR genes in tumor and peritumoral tissues
Note: * — p < 0.05
The ARIH2 gene is expressed everywhere, demonstrating the highest levels of expression in granulocytes [15]. Ubiquitin-protein ligase E3, encoded by the ARIH2 gene, catalyzes the ubiquitination of target proteins and plays a key role in posttranslational modifications in various cellular processes. ARIH2 is involved in DNA repair under genotoxic stress [16].
The family of solute carrier proteins 26 (SLC26) includes multifunctional transporters of substrates, including oxalate, sulfate, and chloride, and plays an important role in the physiology and pathophysiology of the kidneys [17]. One of the members of this family, SLC26A6, is of particular interest because it has some non-canonical properties. For example, it has recently been demonstrated that SLC26A6 acts as an oncogene in hepatocellular carcinoma [18] and lung cancer [19]. In the studied samples, the expression levels of the ARIH2 and SLC26A6 genes were approximately the same in the tumor and peritumoral tissues (Figure 6).
Ubiquitination is one of the types of protein modification that modulates many cellular signaling processes, including DNA repair, transcription, cell membrane receptor recycling, intracellular transport, endocytosis, angiogenesis, and inflammatory signaling [20]. Ubiquitination occurs as a result of the joint work of three types of enzymes: ubiquitin-activating enzymes (E1), ubiquitin-conjugating enzymes (E2) and ubiquitin ligases (E3), respectively (Upregulation of ubiquitin-conjugating enzyme E2Z is associated with human hepatocellular carcinoma). More and more studies show that most of the enzymes involved in ubiquitination play a significant role in the development of tumors [21]. Paired homeodomain transcription factor 1 (PITX1), also known as pituitary homeobox 1 (Ptx1), refers to highly conserved homeobox genes that encode sequence-specific transcription factors (SSTFS) that are involved in osteogenesis [22]. It is assumed that PITX1 can act as a tumor suppressor gene and a potential biomarker for predicting the chemoresistance of tumor stem cells of HNSCC [23]. In our study, a decrease in the expression of this gene was noted in the samples of the tumor tissue of the HNSCC, compared with the tissue of the peritumoral region (Figure 7).
Figure 6. The level of relative expression of the ARIH2, SLC26A6 genes in tumor and peritumoral tissues
Figure 7. The level of relative expression of the UBE2Z and PITX1 genes in tumor and peritumoral tissues
Note: * — p < 0.05
Conclusion
Increased expression of EGFR and PIK3CA genes in tumor tissue confirms the activation of signaling pathways associated with tumor cell proliferation, survival, and progression. In contrast, the higher expression of the putative tumor suppressor gene PITX1 in peritumoral tissue suggests the preservation of regulatory mechanisms limiting malignant transformation outside the tumor focus.
The obtained results emphasize the importance of studying not only the tumor itself but also its surrounding peritumoral microenvironment, which may contribute to disease progression and recurrence. The identified molecular markers can be considered promising candidates for further studies aimed at improving prognostic assessment, identifying patients at high risk of relapse, and developing personalized therapeutic strategies for HNSCC.
About the authors
Enar D. Jumaniyazova
RUDN University
Author for correspondence.
Email: enar2017@yandex.ru
ORCID iD: 0000-0002-8226-0433
SPIN-code: 1780-5326
Moscow, Russian Federation
Irina V. Arutyunyan
RUDN University; Avtsyn Research Institute of Human Morphology, Petrovsky National Research Centre of Surgery
Email: enar2017@yandex.ru
ORCID iD: 0000-0002-4344-8943
SPIN-code: 5220-1893
Moscow, Russian Federation
Anna G. Soboleva
RUDN University; Avtsyn Research Institute of Human Morphology, Petrovsky National Research Centre of Surgery
Email: enar2017@yandex.ru
ORCID iD: 0000-0002-9158-1933
SPIN-code: 2582-5511
Moscow, Russian Federation
Polina A. Vishnyakova
RUDN University; V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology and Perinatology
Email: enar2017@yandex.ru
ORCID iD: 0000-0001-8650-8240
SPIN-code: 3406-3866
Moscow, Russian Federation
Marina A. Gulieva
RUDN University
Email: enar2017@yandex.ru
SPIN-code: 3536-3784
Moscow, Russian Federation
Anastasia V. Lokhonina
RUDN University
Email: enar2017@yandex.ru
ORCID iD: 0000-0001-8077-2307
SPIN-code: 4521-2250
Moscow, Russian Federation
Andrey V. Makarov
RUDN University; Pirogov Russian National Research Medical University
Email: enar2017@yandex.ru
ORCID iD: 0000-0003-2133-2293
SPIN-code: 3534-3764
Moscow, Russian Federation
Konstantin B. Gordon
RUDN University; A. Tsyb Medical Radiological Research Center, National Medical Research Center of Radiology
Email: enar2017@yandex.ru
ORCID iD: 0000-0002-3146-5615
SPIN-code: 2045-4565
Moscow, Russian Federation; Obninsk, Russian Federation
References
- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2021;71(3):209–249. doi: 10.3322/caac.21660
- Barsouk A, Aluru J S, Rawla P, Saginala K, Barsouk A. Epidemiology, risk factors, and prevention of head and neck squamous cell carcinoma. Medical Sciences. 2023;11(2):42. doi: 10.3390/medsci11020042
- Jumaniyazova ED, Sentyabreva АV, Kosyreva АМ, Lokhonina АV. Molecular genetic signatures of head and neck squamous cell carcinoma and their changes induced by proton irradiation. RUDN Journal of Medicine. 2024;28(4):413–426. doi: 10.22363/2313–0245–2024–28–4–413–426
- Eden D, Ghose A, Moschetta M, Perez-Fidalgo J A, Rassy E, Boussios S. Immunotherapy combined with standard therapies in head and neck squamous cell carcinoma–a meta-analysis. Anticancer Research. 2024;44(3):861–878. doi: 10.21873/anticanres.16880
- Machiels J P, Leemans C R, Golusinski W, Grau C, Licitra L, Gregoire V. Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS–ESMO–ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2020;31(11):1462–1475. doi: 10.1016/j.annonc.2020.07.011
- Ionna F, Bossi P, Guida A, Alberti A, Muto P, Salzano G, Perri F. Recurrent/metastatic squamous cell carcinoma of the head and neck: a big and intriguing challenge which may be resolved by integrated treatments combining locoregional and systemic therapies. Cancers. 2021;13(10):2371. doi: 10.3390/cancers13102371
- Samra B, Tam E, Baseri B, Shapira I. Checkpoint inhibitors in head and neck cancer: current knowledge and perspectives. Journal of Investigative Medicine. 2018;66(7):1023–1030. doi: 10.1136/jim‑2018–000743
- Squarize CH, Castilho RM, Abrahao A C, Molinolo A, Lingen MW, Gutkind JSL. PTEN deficiency contributes to the development and progression of head and neck cancer. Neoplasia. 2013;15(5):461–471. doi: 10.1593/neo.121024
- Vidotto T, Melo CM, Castelli E, Koti M, Dos Reis RB, Squire JA. Emerging role of PTEN loss in evasion of the immune response to tumours. British journal of cancer. 2020;122(12):1732–1743. doi: 10.1038/s41416–020–0834–6
- Segrelles C, Paramio JM, Lorz C. The transcriptional co-activator YAP: A new player in head and neck cancer. Oral Oncology. 2018;86:25–32. doi: 10.1016/j.oraloncology.2018.08.020
- Abdel-Hamid N M, Abass S A. Matrix metalloproteinase contribution in management of cancer proliferation, metastasis and drug targeting. Molecular biology reports. 2021;48(9):6525–6538. doi: 10.1007/s11033–021–06635‑z
- Vanhaesebroeck B, Stephens L, Hawkins P. PI3K signalling: the path to discovery and understanding. Nature reviews Molecular cell biology. 2012;13(3):195–203. doi: 10.1038/nrm3290
- Rothenberg SM, Ellisen LW. The molecular pathogenesis of head and neck squamous cell carcinoma. The Journal of clinical investigation. 2012;122(6):1951–1957. doi: 10.1172/JCI59889
- Hong Y, He J, Deng D, Liu Q, Zu X, Shen Y. Targeting kinases that regulate programmed cell death: a new therapeutic strategy for breast cancer. Journal of Translational Medicine. 2025;23(1):439. doi: 10.1186/s12967–025–06367–9.
- Vinci M, Treccarichi S, Galati Rando R, Musumeci A, Todaro V, Federico Calì F. A de novo ARIH2 gene mutation was detected in a patient with autism spectrum disorders and intellectual disability. Scientific Reports. 2024;14(1):15848. doi: 10.1038/s41598–024–66475–2
- Von Stechow L, Typas D, Carreras Puigvert J, Oort L, Siddappa R, Pines A Danen EH. The E3 ubiquitin ligase ARIH1 protects against genotoxic stress by initiating a 4EHP-mediated mRNA translation arrest. Molecular and cellular biology. 2015; 35(7): 1254–1268. doi: 10.1128/mcb.01152–14
- Li J, Huang S, Liu S, Liao X, Yan S, Liu Q. SLC26 family: a new insight for kidney stone disease. Frontiers in Physiology. 2023;14:1118342. doi: 10.3389/fphys.2023.1118342
- Cao J, Wang P, Chen J, He X. Systemic characterization of the SLC family genes reveals SLC26A6 as a novel oncogene in hepatocellular carcinoma. Translational Cancer Research. 2021;10(6):2882. doi: 10.21037/tcr‑20–1751
- Lee D, Lee P C, Hong JH, Shin DM. Estrogen treatment reduced oxalate transporting activity and enhanced migration through the involvement of SLC26A6 in lung cancer cells. Toxicology in Vitro. 2023;82:105373. doi: 10.1016/j.tiv.2022.105373
- Bui QT, Hong JH, Kwak M, Lee JY, Lee PCW. Ubiquitin-conjugating enzymes in cancer. Cells. 2021;10(6): 1383. doi: 10.3390/cells10061383.
- Shi X, Wang B, Chen X, Zheng Y, Ding Y, Wang C. Upregulation of ubiquitin-conjugating enzyme E2Z is associated with human hepatocellular carcinoma. Biochemical and Biophysical Research Communications. 2020;523(1):25–32. doi: 10.1016/j.bbrc.2019.11.170
- Kioussi C, Shih H P, Loflin J, Gross MK. Prediction of active nodes in the transcriptional network of neural tube patterning. Proceedings of the National Academy of Sciences. 2006;103(49):18621–18626. doi: 10.1073/pnas.0609055103
- Takenobu M, Osaki M, Fujiwara K, Fukuhara T, Kitano H, Kugoh H, Okada F. PITX1 is a novel predictor of the response to chemotherapy in head and neck squamous cell carcinoma. Molecular and Clinical Oncology. 2016;5(1):89–94. doi: 10.3892/mco.2016.880
Supplementary files

















